Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies

Michael M. Graham, Lanell M. Peterson, Jeanne Link, Margaret L. Evans, Janet S. Rasey, Wui Jin Koh, James H. Caldwell, Kenneth Krohn

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Fluoromisonidazole (FMISO), labeled with the positron emitter 18F, is a useful hypoxia imaging agent for PET studies, with potential applications in patients with tumors, cardiovascular disease and stroke. Methods: Radiation doses were calculated in patients undergoing imaging studies to help define the radiation risk of FMISO-PET imaging. Time-dependent concentrations of radioactivity were determined in blood samples and PET images of patients following intravenous injection of [18F]FMISO. Radiation absorbed doses were calculated using the procedures of the Medical Internal Radiation Dose (MIRD) committee, taking into account the variation in dose based on the distribution of activities observed in the individual patients. As part of this study we also calculated an S value for brain to eye. Effective dose equivalent was calculated using ICRP 60 weights. Results: Effective dose equivalent was 0.013 mSv/MBq in men and 0.014 mSv/MBq in women. Individual organ doses for women were not different from men. Assuming bladder voiding at 2- or 4-hr intervals, the critical organ that received the highest dose was the urinary bladder wall (0.021 mGy/MBq with 2-hr voiding intervals or 0.029 mGy/MBq with 4-hr voiding intervals). Conclusion: The organ doses for [18F]FMISO are comparable to those associated with other commonly performed nuclear medicine tests and indicate that potential radiation risks associated with this study are within generally accepted limits.

Original languageEnglish (US)
Pages (from-to)1631-1636
Number of pages6
JournalJournal of Nuclear Medicine
Volume38
Issue number10
StatePublished - Oct 1997
Externally publishedYes

Fingerprint

Radiometry
Fluorine
Radiation
Urinary Bladder
Nuclear Medicine
Intravenous Injections
Radioactivity
Cardiovascular Diseases
Myocardial Infarction
fluoromisonidazole
Electrons
Weights and Measures
Brain
Neoplasms

Keywords

  • Dosimetry
  • Fluorine-18-fluoromisonidazole
  • Monte Carlo simulations

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Graham, M. M., Peterson, L. M., Link, J., Evans, M. L., Rasey, J. S., Koh, W. J., ... Krohn, K. (1997). Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. Journal of Nuclear Medicine, 38(10), 1631-1636.

Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. / Graham, Michael M.; Peterson, Lanell M.; Link, Jeanne; Evans, Margaret L.; Rasey, Janet S.; Koh, Wui Jin; Caldwell, James H.; Krohn, Kenneth.

In: Journal of Nuclear Medicine, Vol. 38, No. 10, 10.1997, p. 1631-1636.

Research output: Contribution to journalArticle

Graham, MM, Peterson, LM, Link, J, Evans, ML, Rasey, JS, Koh, WJ, Caldwell, JH & Krohn, K 1997, 'Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies', Journal of Nuclear Medicine, vol. 38, no. 10, pp. 1631-1636.
Graham MM, Peterson LM, Link J, Evans ML, Rasey JS, Koh WJ et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. Journal of Nuclear Medicine. 1997 Oct;38(10):1631-1636.
Graham, Michael M. ; Peterson, Lanell M. ; Link, Jeanne ; Evans, Margaret L. ; Rasey, Janet S. ; Koh, Wui Jin ; Caldwell, James H. ; Krohn, Kenneth. / Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. In: Journal of Nuclear Medicine. 1997 ; Vol. 38, No. 10. pp. 1631-1636.
@article{c579b5b698c54c708222d56391567c69,
title = "Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies",
abstract = "Fluoromisonidazole (FMISO), labeled with the positron emitter 18F, is a useful hypoxia imaging agent for PET studies, with potential applications in patients with tumors, cardiovascular disease and stroke. Methods: Radiation doses were calculated in patients undergoing imaging studies to help define the radiation risk of FMISO-PET imaging. Time-dependent concentrations of radioactivity were determined in blood samples and PET images of patients following intravenous injection of [18F]FMISO. Radiation absorbed doses were calculated using the procedures of the Medical Internal Radiation Dose (MIRD) committee, taking into account the variation in dose based on the distribution of activities observed in the individual patients. As part of this study we also calculated an S value for brain to eye. Effective dose equivalent was calculated using ICRP 60 weights. Results: Effective dose equivalent was 0.013 mSv/MBq in men and 0.014 mSv/MBq in women. Individual organ doses for women were not different from men. Assuming bladder voiding at 2- or 4-hr intervals, the critical organ that received the highest dose was the urinary bladder wall (0.021 mGy/MBq with 2-hr voiding intervals or 0.029 mGy/MBq with 4-hr voiding intervals). Conclusion: The organ doses for [18F]FMISO are comparable to those associated with other commonly performed nuclear medicine tests and indicate that potential radiation risks associated with this study are within generally accepted limits.",
keywords = "Dosimetry, Fluorine-18-fluoromisonidazole, Monte Carlo simulations",
author = "Graham, {Michael M.} and Peterson, {Lanell M.} and Jeanne Link and Evans, {Margaret L.} and Rasey, {Janet S.} and Koh, {Wui Jin} and Caldwell, {James H.} and Kenneth Krohn",
year = "1997",
month = "10",
language = "English (US)",
volume = "38",
pages = "1631--1636",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "10",

}

TY - JOUR

T1 - Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies

AU - Graham, Michael M.

AU - Peterson, Lanell M.

AU - Link, Jeanne

AU - Evans, Margaret L.

AU - Rasey, Janet S.

AU - Koh, Wui Jin

AU - Caldwell, James H.

AU - Krohn, Kenneth

PY - 1997/10

Y1 - 1997/10

N2 - Fluoromisonidazole (FMISO), labeled with the positron emitter 18F, is a useful hypoxia imaging agent for PET studies, with potential applications in patients with tumors, cardiovascular disease and stroke. Methods: Radiation doses were calculated in patients undergoing imaging studies to help define the radiation risk of FMISO-PET imaging. Time-dependent concentrations of radioactivity were determined in blood samples and PET images of patients following intravenous injection of [18F]FMISO. Radiation absorbed doses were calculated using the procedures of the Medical Internal Radiation Dose (MIRD) committee, taking into account the variation in dose based on the distribution of activities observed in the individual patients. As part of this study we also calculated an S value for brain to eye. Effective dose equivalent was calculated using ICRP 60 weights. Results: Effective dose equivalent was 0.013 mSv/MBq in men and 0.014 mSv/MBq in women. Individual organ doses for women were not different from men. Assuming bladder voiding at 2- or 4-hr intervals, the critical organ that received the highest dose was the urinary bladder wall (0.021 mGy/MBq with 2-hr voiding intervals or 0.029 mGy/MBq with 4-hr voiding intervals). Conclusion: The organ doses for [18F]FMISO are comparable to those associated with other commonly performed nuclear medicine tests and indicate that potential radiation risks associated with this study are within generally accepted limits.

AB - Fluoromisonidazole (FMISO), labeled with the positron emitter 18F, is a useful hypoxia imaging agent for PET studies, with potential applications in patients with tumors, cardiovascular disease and stroke. Methods: Radiation doses were calculated in patients undergoing imaging studies to help define the radiation risk of FMISO-PET imaging. Time-dependent concentrations of radioactivity were determined in blood samples and PET images of patients following intravenous injection of [18F]FMISO. Radiation absorbed doses were calculated using the procedures of the Medical Internal Radiation Dose (MIRD) committee, taking into account the variation in dose based on the distribution of activities observed in the individual patients. As part of this study we also calculated an S value for brain to eye. Effective dose equivalent was calculated using ICRP 60 weights. Results: Effective dose equivalent was 0.013 mSv/MBq in men and 0.014 mSv/MBq in women. Individual organ doses for women were not different from men. Assuming bladder voiding at 2- or 4-hr intervals, the critical organ that received the highest dose was the urinary bladder wall (0.021 mGy/MBq with 2-hr voiding intervals or 0.029 mGy/MBq with 4-hr voiding intervals). Conclusion: The organ doses for [18F]FMISO are comparable to those associated with other commonly performed nuclear medicine tests and indicate that potential radiation risks associated with this study are within generally accepted limits.

KW - Dosimetry

KW - Fluorine-18-fluoromisonidazole

KW - Monte Carlo simulations

UR - http://www.scopus.com/inward/record.url?scp=0030761836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030761836&partnerID=8YFLogxK

M3 - Article

C2 - 9379204

AN - SCOPUS:0030761836

VL - 38

SP - 1631

EP - 1636

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 10

ER -